Samsung Biologics America (SBA), the U.S. subsidiary of Samsung Biologics, has posted its strongest financial performance to date. Industry experts view this as a clear sign that the company’s global expansion strategy, centered on local sales operations, is paying off.
Financial reports filed with South Korea’s Financial Supervisory Service on Tuesday show that SBA generated revenue of 136.68 billion KRW (approximately 88.9 million USD) and net profit of 6.96 billion KRW (approximately 4.5 million USD) last year. While revenue dipped 9.18% from the previous year, the company successfully turned a profit.
Last year’s net profit marks a record high since SBA’s establishment in 2020. Despite initial performance declines following its launch, analysts attribute the improved profitability to streamlined operations and cost-cutting measures, including the closure of its San Francisco office.
SBA’s financial journey has been a rollercoaster ride. After posting a modest net profit of 45 million KRW (approximately 29,200 USD) in its inaugural year, earnings climbed to 4.4 billion KRW (approximately 2.9 million USD) in 2021. However, profits then declined to 3.76 billion KRW (approximately 2.4 million USD) in 2022 and 2.55 billion KRW (approximately 1.7 million USD) in 2023. The company hit a bump in 2024, reporting a net loss of 9.43 billion KRW (approximately 6.1 million USD).
Revenue, however, has generally trended upward. From 11.3 billion KRW (approximately 7.4 million USD) in 2020, sales skyrocketed to 68.42 billion KRW (approximately 44.5 million USD) in 2021, before a slight dip to 63.27 billion KRW (approximately 41.2 million USD) in 2022. The company rebounded strongly, with revenue reaching 129.86 billion KRW (approximately 84.5 million USD) in 2023 and projected to hit 150.5 billion KRW (approximately 97.9 million USD) in 2024. Despite this growth trajectory, last year’s revenue settled at 136.68 billion KRW (approximately 88.9 million USD).
Established in 2020, SBA is a wholly-owned subsidiary tasked with expanding Samsung Biologics’ contract development organization (CDO) business globally. With offices in New Jersey and Boston, SBA has become a crucial sales hub for securing international orders, especially given Samsung Biologics’ lack of overseas production facilities.
SBA’s record-breaking performance is seen as concrete evidence of its success in broadening its global customer base. Experts say this goes beyond mere financial improvement, indicating that Samsung Biologics’ global expansion strategy is yielding tangible results.
As Samsung Biologics moves to establish production facilities in the U.S., SBA’s role is expected to evolve. While it has primarily served as a liaison with global pharmaceutical companies, SBA is likely to take on a more integrated role, strengthening connections between local production sites and international clients.
In a significant move last December, Samsung Biologics inked a deal to acquire GlaxoSmithKline’s Human Genome Sciences (HGS) biopharmaceutical production facility in Rockville, Maryland. To fund this acquisition and cover operational costs, the company raised approximately 520 billion KRW (about 338 million USD) through a capital increase.